☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
bio-thera
Bio-Thera Reports the EMA’s Approval of Avzivi (Biosimilar, Avastin) for Treating Multiple Indications
July 30, 2024
Bio-Thera Reports the Regulatory Filing Acceptance for BAT2206 (Biosimilar, Stelara) Across the US and EU
July 24, 2024
Bio-Thera Gains the CHMP’s Positive Opinion of Avzivi (Biosimilar, Avastin)
June 3, 2024
Bio-Thera Collaborates with STADA for the Commercialization of BAT2506 (Biosimilar, Simponi)
May 29, 2024
Bio-Thera Reports the US FDA’s Approval of Avzivi (Biosimilar, Avastin)
December 8, 2023
Bio-Thera Reports the Results for BAT2206 in P-III Trial for the Treatment of Plaque Psoriasis
December 6, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.